Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Relugolix 120 MG Clear all
Terminated Phase 1 Interventional

A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients

NCT05679388
View directory record Official record
Conditions
Prostate Cancer, Prostate Cancer Metastatic, Prostate Adenocarcinoma
Interventions
Relugolix Pill, Ritonavir, Itraconazole
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 2, 2026, 5:33 AM EDT
Recruiting Phase 1Phase 2 Interventional

Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer

NCT07182279
View directory record Official record
Conditions
Prostate Cancer (Adenocarcinoma)
Interventions
Brachytherapy
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
40 Years and older · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 2, 2026, 5:33 AM EDT
Completed Phase 1 Interventional

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

NCT04666129
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer, Metastatic Castration-Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer
Interventions
Relugolix, Abiraterone, Prednisone, Methylprednisolone, Apalutamide, Docetaxel
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
16
States / cities
Tucson, Arizona • Little Rock, Arkansas • Lakewood, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2025 · Synced Sep 2, 2026, 5:33 AM EDT
Completed No phase listed Observational

A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX

NCT05467176
View directory record Official record
Conditions
Prostate Cancer
Interventions
Relugolix
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
96
States / cities
Homewood, Alabama • Mobile, Alabama • Phoenix, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 2, 2026, 5:33 AM EDT
Recruiting Phase 2 Interventional

The SUGAR Study; SBRT and Relugolix) for Prostate Cancer

NCT06111781
View directory record Official record
Conditions
Prostate Cancer
Interventions
Relugolix 120 MG [Orgovyx], SBRT standard of care radiotherapy treatment
Drug · Radiation
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
4
States / cities
New Haven, Connecticut • Lebanon, New Hampshire • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 2, 2026, 5:33 AM EDT
Completed Early Phase 1 Interventional

Pilot Study: Androgen Deprivation Therapy Impact on PSMA-PET Sensitivity in Prostatectomy Staging

NCT07069465
View directory record Official record
Conditions
Prostate Cancer
Interventions
flotufolastat F 18, Relugolix 120 MG, Serum PSA and Testosterone
Diagnostic Test · Drug
Lead sponsor
Urology Clinics of North Texas
Network
Eligibility
Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Sep 2, 2026, 5:33 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer

NCT02083185
View directory record Official record
Conditions
Prostate Cancer
Interventions
Relugolix, Leuprorelin
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
19
States / cities
Birmingham, Alabama • San Diego, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Sep 2, 2026, 5:33 AM EDT
Recruiting Phase 1 Interventional

Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer

NCT06631521
View directory record Official record
Conditions
Prostate CA, Prostate Cancer (Adenocarcinoma), Prostate Cancer Surgery
Interventions
Darolutamide, Relugolix, Radical Prostatectomy
Drug · Procedure
Lead sponsor
AdventHealth
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 2, 2026, 5:33 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer

NCT03085095
View directory record Official record
Conditions
Prostate Cancer
Interventions
Relugolix, Leuprolide Acetate
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
27
States / cities
Tucson, Arizona • Orange, California • Denver, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2022 · Synced Sep 2, 2026, 5:33 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer

NCT02135445
View directory record Official record
Conditions
Prostate Cancer
Interventions
TAK-385, Degarelix
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
19
States / cities
Birmingham, Alabama • San Diego, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Sep 2, 2026, 5:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioavailability and Effect of Food on TAK-385 Tablet Formulations in Healthy Participants

NCT02396147
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-385 T2 Formulation, TAK-385 T4 Formulation B, TAK-385 T4 Formulation C
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 24, 2016 · Synced Sep 2, 2026, 5:33 AM EDT
Recruiting Phase 2 Interventional

Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT

NCT07455903
View directory record Official record
Conditions
Prostate Cancer, Localized Prostate Carcinoma
Interventions
Leuprolide, Degarelix, Relugolix, Triptorelin, Bicalutamide, 18-F Flotufolastat PSMA PET, Radical prostatectomy
Drug · Diagnostic Test · Procedure
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 2, 2026, 5:33 AM EDT
Completed Phase 2 Interventional Results available

A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases

NCT04523207
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Apalutamide, ADT, Relugolix
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
32
States / cities
Tucson, Arizona • Little Rock, Arkansas • Sherman Oaks, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 2, 2026, 5:33 AM EDT
Completed Phase 3 Interventional Results available

Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate

NCT05605964
View directory record Official record
Conditions
Prostate Cancer
Interventions
Relugolix, Leuprolide Acetate
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
108
States / cities
Mobile, Alabama • Tucson, Arizona • Little Rock, Arkansas + 83 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 2, 2026, 5:33 AM EDT
Recruiting Phase 1 Interventional

Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

NCT06130995
View directory record Official record
Conditions
Androgen Deprivation Therapy, Locally Advanced Prostate Cancer
Interventions
Relugolix and Enzalutamide
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older · Male only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 2, 2026, 5:33 AM EDT
Recruiting Phase 2 Interventional

The University of Miami Adapt (UAdapt) Trial

NCT06111313
View directory record Official record
Conditions
Prostate Cancer
Interventions
FTLEAD, Ultra-Short-Term Androgen Deprivation Therapy with Relugolix, HypoLEAD, ADT Standard of Care
Radiation · Drug
Lead sponsor
University of Miami
Other
Eligibility
35 Years to 85 Years · Male only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 2, 2026, 5:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Effects of Erythromycin on the Pharmacokinetics of Relugolix, Estradiol, and Norethindrone in Healthy Postmenopausal Women and on the Pharmacokinetics of Relugolix in Healthy Adult Men

NCT04714554
View directory record Official record
Conditions
Healthy
Interventions
Relugolix/E2/NETA FDC, Relugolix, Erythromycin
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Hialeah, Florida
Source: ClinicalTrials.gov public record
Updated Aug 31, 2021 · Synced Sep 2, 2026, 5:33 AM EDT